• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: 9 out of 10 pharma companies have dedicated health economics, outcomes research groups

Report: 9 out of 10 pharma companies have dedicated health economics, outcomes research groups

April 6, 2015
CenterWatch Staff

Dedicated health economics and outcomes research (HEOR) teams that develop data to demonstrate a cohesive value proposition to payers are a vital part of a successful managed markets strategy, according to a new report by life sciences intelligence firm Cutting Edge Information.

The study, Building World-Class HEOR Teams: Creating Convincing Value Proposition for Payers, found 89% of companies now have some type of dedicated HEOR group within their structure. Global health economics teams at large companies provide support for country-level managed markets teams. Country-level teams often conduct independent health economics research in response to specific payer needs.

“A significant advantage of dedicated groups is the ability to develop multiyear plans that fully explore the health economics and outcomes of each company’s products,” said Jacob Presson, senior research analyst at Cutting Edge Information. “On average, surveyed teams dedicate the largest headcount to HEOR analysts—the essential team members responsible for collecting and working with pharmacoeconomic data.”

Dedicated HEOR teams can interface directly with managed markets account managers to ensure that they are trained to either deliver health economics data to payers or to bring in health outcomes liaisons or medical science liaisons that specialize in presenting comprehensive pharmacoeconomic data.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing